Business / Finance

RSS

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

Alvotech, a powerful new player in the field of biopharmaceuticals, today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies.

5 Dec 2013

Roche signs research collaboration and licensing agreement with Molecular Partners

Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners' DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

4 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

Ligand Pharmaceuticals Incorporated is revising upward its previous revenue and net income guidance for the fourth quarter and full year 2013 as a result of higher-than-expected sales of Captisol® material.

4 Dec 2013

Getinge proposes to acquire Pulsion Medical Systems

Getinge intends to issue a public tender offer to acquire all shares in Pulsion Medical Systems SE ("Pulsion"), listed on the German Stock Exchange (Deutsche Börse).

4 Dec 2013

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

Finnish healthcare company Biohit Oyj and American company Dynex Technologies, Inc. have signed an agreement for the distribution of the two-microplate DS2®, four-microplate DSX® and 12-microplate Agility® automated ELISA (enzyme-linked immunosorbent assay) processing systems, for use with the Biohit Oyj GastroPanel.

4 Dec 2013

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

4 Dec 2013

Lucane Pharma, Medunik Canada to offer new therapeutic option for patients suffering from UCD

Medunik Canada, a pharmaceutical company specialized in orphan drugs and Lucane Pharma, a French niche pharmaceutical company, announced the conclusion of an exclusive collaboration agreement.

4 Dec 2013

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Cell Therapeutics, Inc. (CTI) announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for PIXUVRI® (pixantrone).

4 Dec 2013

Nanologix collaborates with Saudi company to distribute Nanologix products in Arabian Gulf region

NanoLogix, Inc. an innovator in the rapid detection, identification of live bacteria, and determination of their antibiotic resistance and sensitivity, announces that they are working with Nasaem-Aljazira, a Saudi Arabian company headquartered in Riyadh, to establish exclusive distribution and/or manufacturing of NanoLogix products in Saudi Arabia and the Arabian Gulf region, also known as the Gulf Cooperation Council (GCC) area.

4 Dec 2013

HyGreen, HCS-Medical partner to build strategic relationships with federal healthcare markets

HyGreen, Inc., maker of the first electronic hand hygiene reminding and recording system, announced today a partnership and distribution agreement with HCS-Medical to build strategic relationships with federal healthcare markets and distribute its HyGreen Hand Hygiene System.

3 Dec 2013

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII should be developed.

3 Dec 2013

White paper discusses the effects of particle shape and size on the properties of medical materials

Ceram, the international materials technology company, has published a new white paper for the medical devices industry, ‘The Effects of Particle Size Distribution on the Properties of Medical Materials’.

3 Dec 2013

EMD Serono's TocopheRx to focus on development of oral FSH agonists for infertility treatment

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today the creation of TocopheRx, a Boston-based spin-off company resulting from the Entrepreneur Partnership Program launched by Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, in April 2012.

3 Dec 2013

Apollo Endosurgery acquires the obesity intervention division of Allergan

Apollo Endosurgery, Inc., a leading developer of medical devices for endoscopic surgical procedures, today announced the completion of the acquisition of the obesity intervention division of Allergan, Inc., which manufactures and sells weight loss solutions comprised of the LAP-BAND adjustable gastric banding system and the ORBERA intra-gastric balloon system.

3 Dec 2013

Alliance HealthCare Services, ONRAD form strategic affiliation to provide quality services to customers

Alliance HealthCare Services, Inc., a leading national provider of radiology and radiation therapy services, and ONRAD, Inc., a full service radiology provider, have agreed to establish a strategic affiliation to develop and support opportunities to further enhance access to the quality services each company provides to its customers.

2 Dec 2013

Xagenic announces closing of $20 million Series B financing

Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, today announced the close of a Series B financing totaling $20 million. The round was led by new investor Domain Associates, LLC, which was joined by existing investors including CTI Life Sciences Fund and the Ontario Emerging Technologies Fund.

2 Dec 2013

Shire signs agreement to supply authorized generic version of Adderall XR

Shire plc, announces that its subsidiary Shire US Inc. has entered into an agreement to supply an authorized generic version of its product Adderall XR.

2 Dec 2013

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Visterra, Inc., a developer of novel therapeutics to prevent and treat major infectious diseases, today announced that it has received $8.1 million in proceeds from an upsized and final closing of its Series A financing round. The company also announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, which follows the recent appointment of Brian Pereira, M.D. as President and Chief Executive Officer of Visterra this past summer.

2 Dec 2013

Cell Therapeutics gets $5 million payment from Teva for TRISENOX

Cell Therapeutics, Inc. today announced that it has received a $5 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of a sales milestone for TRISENOX (arsenic trioxide).

2 Dec 2013

Business / Finance

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

Roche signs research collaboration and licensing agreement with Molecular Partners

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Ligand revises previous revenue and net income guidance for fourth quarter and full year 2013

Getinge proposes to acquire Pulsion Medical Systems

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Lucane Pharma, Medunik Canada to offer new therapeutic option for patients suffering from UCD

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Nanologix collaborates with Saudi company to distribute Nanologix products in Arabian Gulf region

HyGreen, HCS-Medical partner to build strategic relationships with federal healthcare markets

Biotest, EpiVax partner to develop novel, non-immunogenic Factor VIII for hemophilia treatment

White paper discusses the effects of particle shape and size on the properties of medical materials

EMD Serono's TocopheRx to focus on development of oral FSH agonists for infertility treatment

Apollo Endosurgery acquires the obesity intervention division of Allergan

Alliance HealthCare Services, ONRAD form strategic affiliation to provide quality services to customers

Xagenic announces closing of $20 million Series B financing

Shire signs agreement to supply authorized generic version of Adderall XR

Visterra gets $8.1M in proceeds from upsized and final closing of Series A financing round

Cell Therapeutics gets $5 million payment from Teva for TRISENOX

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News